SynthesisBMC cancer2026
Prostate cancer screening and associated factors in Ethiopia: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is a leading cause of cancer-related morbidity and mortality among men worldwide. Despite its growing burden, screening uptake remains low in many low- and middle-income countries, including Ethiopia. Early detection through screening is essential, yet awareness and access remain limited.
methodsThis systematic review and meta-analysis followed PRISMA guidelines. We searched PubMed, Scopus, Web of Science, AJOL, and Google Scholar for studies published 30 August 2025 using terms related to prostate cancer, screening, and Ethiopia. Observational studies of prostate cancer screening were included. Two reviewers independently screened studies, extracted data, and assessed quality using the Newcastle-Ottawa Scale. Pooled prevalence was estimated with a random-effects meta-analysis; heterogeneity and publication bias were evaluated using I² and funnel plots with Egger's test. Significant factors were summarized narratively.
resultsTwelve studies, including 7526 participants from Addis Ababa, Southern, Central, and Amhara regions, were analyzed. The pooled prevalence of prostate cancer screening was 30.37% (95% CI: 20.49-40.25% I² = 96.7%, p < 0.001). Subgroup analysis showed the highest prevalence in the Wolaita Sodo (63.08%, 95% CI: 58.73-69.22%), followed by Amhara region (47.97%( 95% CI: 42.02-53.92), and the lowest in central Ethiopia region (7.19%, 95% CI: 4.75-9.67%). Significantly associated factors included awareness of prostate cancer screening (AOR = 3.36, 95% CI: 1.87-6.85), age of the patients > 45 years (AOR = 3.53, 95% CI: 1.69-5.46), regular checkup of cancer (AOR = 3.65, 95% CI: 1.09-6.20), average income ≥ 5000 ETB (AOR = 3.80, 95% CI: 2.28-5.31), family history of prostate cancer (AOR = 3.87,95% CI: 2.30-5.45), and ever heard about prostate cancer (AOR = 3.15,95% CI: 1.43-4.88).
conclusionProstate cancer screening in Ethiopia remains low, with marked regional differences. Uptake is higher among older men, those with higher income, prior awareness, family history, or regular health checkups. Targeted educational programs and improved access to screening are urgently needed. Nationwide, longitudinal, and mixed-method studies are essential to evaluate interventions and understand behavioral, cultural, and systemic factors affecting screening practices.
conclusionProstate cancer screening in Ethiopia remains low, with marked regional differences. Uptake is higher among older men, those with higher income, prior awareness, family history, or regular health checkups. Targeted educational programs and improved access to screening are urgently needed. Nationwide, longitudinal, and mixed-method studies are essential to evaluate interventions and understand behavioral, cultural, and systemic factors affecting screening practices.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.